47 results about "Orotic acid" patented technology

The invention belongs to the technical field of gestational diabetes diagnosis marker screening, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application of the biomarker. The invention discloses a biomarker for predicting or diagnosing gestational diabetes mellitus, the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrotachysterol and cycloleucine, and more preferably, the biomarker comprises hypoxanthine, cortisol, dihydrotachysterol, (3R, 4R)-D-ketolactone, creatine, cycloleucine and L-hydroorotic acid. The seven biomarkers disclosed by the invention can predict or diagnose gestational diabetes mellitus independently or jointly through plasma detection at the early pregnancy stage, effectively improve the early diagnosis rate of gestational diabetes mellitus and improve disease prognosis, and have clinical use and popularization values.

Methods of treating or ameliorating multiple sclerosis by the dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus or a pharmaceutically acceptable salt and / or a solvate, in particular a hydrate, thereof or a solvate, in particular a hydrate, of a pharmaceutically acceptable salt thereof, by administering to a human patient a therapeutically effective amount of the DHODH inhibitor, more specifically a daily dose of about 10 mg to about 45 mg.

The invention provides a salt type crystal of octreotide as well as a preparation method and application of the salt type crystal. The crystal has characteristic peaks when the 2 theta value is 7.7 degrees + / -0.2 degrees, 8.7 degrees + / -0.2 degrees, 9.5 degrees + / -0.2 degrees, 10.2 degrees + / -0.2 degrees, 13.6 degrees + / -0.2 degrees and 18.3 degrees + / -0.2 degrees by using X-ray powder diffraction of Cu-K alpha radiation. The orotate crystal form I of octreotide provided by the invention has the advantages in at least one aspect of solubility, melting point, stability, dissolution rate, hygroscopicity, adhesiveness, fluidity, bioavailability, processability, purification effect, preparation production, safety and the like, and provides a new better choice for preparation of a pharmaceutical preparation containing octreotide; and the method has very important significance on drug development.

The present invention concerns a cell line comprising an endogenous dihydroorotate dehydrogenase (DHODH) and glutamine synthetase (GS) genes which are partially or fully inactivated, and its use for producing recombinant proteins.

The present application relates to the field of cosmetics, and relates to a cosmetic with whitening and sunscreen functions and a preparation method thereof. Calculated by mass percentage, the whitening and sunscreen composition comprises: 0.5% to 5% melanin, 0.1% to 0.5% allantoin, 0.1% to 1% ferulic acid, 0.01% to 0.05% astaxanthin, 0.1% to 0.5% orotic acid; the remainder is water. Chemical sunscreens and physical sunscreens are compounded so that both the internal and external phases of the cosmetic contain sunscreens, which can avoid sunscreen voids to the greatest extent. By compounding melanin, allantoin, ferulic acid, astaxanthin, and orotic acid in a specific ratio and compounding them in the above-mentioned cosmetic formula, the ability of the cosmetic to absorb ultraviolet rays, accelerate wound healing, effectively scavenge free radicals, inhibit inflammatory factors, promote skin renewal, and combine pathways to further improve the product's sunscreen effect.

Provided herein are β-carboline compounds and their use to inhibit dihydroorotate dehydrogenase (DHODH):or a form thereof,wherein R1, R2, R3, R4, Q1, Q2, Q3, Q4, R7, R9, and R11 are as defined herein.

To provide pharmaceutical combinations of treating a clinical condition, e.g., AML.SOLUTION: A pharmaceutical combination comprising a DHODH inhibitor and an anti-CD38 therapeutic agent such as an anti-CD38 antibody is administered to a subject. The pharmaceutical combination can further comprise one or more additional therapeutic agents.SELECTED DRAWING: Figure 2D

The invention relates to the technical field of medicinal chemistry, in particular to salt of a dihydroorotate dehydrogenase inhibitor as well as a preparation method and application of the salt. The salt of the dihydroorotate dehydrogenase inhibitor is a salt of a compound as shown in a formula (I), the salt is sulfate or hydrochloride. Compared with the compound shown in the formula (I), the salt of the compound shown in the formula (I) has better solubility and bioavailability, and has excellent stability.

The present invention belongs to the technical field of biological medicine, and discloses a ceramide compound shown in Chemical Formula I: #imgabs0# wherein, R 1 is selected from the residues after condensation of sialic acid, chelidamic acid monohydrate, 2,5-furandicarboxylic acid, quinic acid, chlorogenic acid, ectoine, nicotinic acid, shikimic acid, glucuronic acid, salicylic acid, carnosic acid, dihydrooat acylanthranilic acid, abietic acid, ursolic acid, tranexamic acid, syringic acid, gentisic acid, vanillic acid, 5-hydroxyisovanillic acid, orotic acid, 5-aminoorotic acid, 3,5-dihydroxy-4-methylbenzoic acid, glycyrrhizic acid or gallic acid, R 2 is selected from one of the following structures: -C 15 H 29 、-C 15 H 31 、-C 15 H 27 、-CHOHC 14 H 27 、-CHOHC 14 H 29 . The present invention also discloses a preparation method and application of the ceramide compound. The present invention introduces a molecular fragment with physiological activity of a functional carboxylic acid into ceramide, which will enhance the original efficacy of this type of molecule and also improve the physicochemical properties of the ceramide compound.

Provided herein are p-carboline compounds of formula (I) [0537], or forms thereof, and uses thereof to inhibit dihydroorotate dehydrogenase (DHODH), wherein R1, R2, R3, R4 and R5 are as defined herein. (I)

Disclosed herein are compounds, i.e., 6-substituted-2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of various disorders and diseases in which inhibition of DHODH is clinically useful, including cancers such as hematological cancers, including acute myeloid leukemia (AML), graft-versus-host disease, autoimmune disorders, and disorders associated with T-cell proliferation. The disclosed compounds may exhibit flip-flop kinetics when orally administered, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of excretion, governs the pharmacokinetics. The disclosed compounds may exhibit a sustained pharmacokinetic profile instead of an immediate-release profile. This Abstract is intended as a scanning tool for purposes of searching within a particular technical field and is not intended to limit the disclosure.

The present invention discloses an Acinetobacter strain producing orotic acid, its application, and a method for producing orotic acid. The Acinetobacter strain producing orotic acid is named Acinetobacter sp WJ01, which was deposited at the General Microbiological Center of the China Center for Type Culture Collection on February 27, 2025, with the deposit number: CGMCC NO: 33667. Compared with the existing engineered bacteria for synthesizing orotic acid, this strain has strong environmental adaptability, can naturally synthesize orotic acid under suitable conditions, has a relatively stable genome, no potential risk of foreign genes, and relatively high safety. During the fermentation process, this Acinetobacter has a high yield and a high sugar-acid conversion rate. Applying the strain of the present invention to the fermentation production of orotic acid can significantly increase the yield of orotic acid and greatly shorten the fermentation period.

The invention discloses a zinc-orotic acid complex crystal material as well as a preparation method and fluorescent recognition application thereof. The chemical formula of the complex is [Zn2 (HOA) 2 (1, 3-dpp) (H2O) 2] n, and the complex has a 2-heavy interspersed two-dimensional network structure. The preparation method comprises the following steps: respectively preparing orotic acid, potassium hydroxide and zinc acetate into solutions, mixing the solutions with 1, 3-bis (4-pyridyl) propane and water, and carrying out ultrasonic treatment and heating treatment to obtain the crystal. The material has characteristic fluorescence emission at 370 nm, the intensity of the material can be obviously changed when encountering a specific substance, and the material can be used as a fluorescence sensing material to identify solvents such as methanol, DMSO, water and the like, specifically detect Fe < 3 + > ions, identify antibiotics dimethylaminotetracycline hydrochloride, furacilin and nitrofurantoin, identify a drug curcumin, and can be used as a fluorescent sensing material. And identifying food additives potassium sorbate and sodium benzoate.

The application discloses a method for catalytically producing 5-fluorouracil and application, and belongs to the technical field of biology. The method uses 5-fluoroorotic acid as a substrate and orotidine-5'-phosphate decarboxylase as a catalyst to efficiently catalyze the synthesis of 5-fluorouracil. The catalytic efficiency is further improved by molecular modification of orotidine-5'-phosphate decarboxylase, the efficient and green production of 5-fluorouracil is realized, and the application of 5-fluorouracil in the fields of medicine and the like is promoted.

To provide a food composition containing equol and an organic acid and having improved flavor, especially aroma.SOLUTION: The food composition contains an organic acid and equol, particularly at least one organic acid selected from the group consisting of carbonic acid, hydrogen carbonate, citric acid, lactic acid, phosphoric acid, gluconic acid, acetic acid, malic acid, orotic acid, ammonium salts thereof, alkali metal salts thereof, alkaline earth metal salts thereof, and chelates thereof, and equol.SELECTED DRAWING: None

The application relates to the technical field of veterinary traditional Chinese medicines, in particular to an anticoccidial combined extract, an anticoccidial composite additive and a preparation method and application thereof, and an anticoccidial product. The anticoccidial combined extract contains Terminalia chebula extract and Saussurea costus extract in a specific mass ratio, has a remarkable anticoccidial effect without other components, can significantly inhibit the activity of dihydroorotate dehydrogenase (DHODH), improve an anticoccidial index (ACI), reduce the oocyst production of coccidia, and reduce the degree of intestinal lesions of chickens caused by coccidia; meanwhile, the anticoccidial combined extract can significantly improve the daily weight gain and daily feed intake of broilers, reduce the feed-meat ratio, and has a double effect of “disease prevention + yield increase”.

The application belongs to the technical field of enzyme engineering, and discloses application of dihydroorotase in reducing purine content. Under specific reaction conditions, dihydroorotase can realize degradation of guanine. The reaction conditions include reaction pH, reaction temperature, and types and concentrations of catalysts. When it is applied to guanine degradation, the reaction pH is 7.0-10.0, the catalyst is a metal ion (Zn 2+ ), the concentration is 0.05-5 mM, and the reaction temperature is 20-45 DEG C. Catalytic reaction of purine substrates by the enzyme reaction conditions provided in the application can realize degradation of guanine, and the application lays a foundation for enzymatic preparation of low-purine food.

This application relates to the field of metabolic engineering and genetic engineering technology for production, specifically providing a uracil-producing strain, its construction method, and its application. This strain is... E. coli Knockout of the uridine kinase gene in the W3110 genome udk Simultaneously integrates the T7 RNA polymerase gene; weakens the uridine kinase gene. pyrH Overexpression of carbamoyl phosphate synthase gene carAB ribose-phosphokinase gene prsA pyrimidine-5'-nucleotide nuclease gene ppnN UMP phosphohydrolase gene umpH and umpG Ribonucleotide hydrolase 1 gene rihA and glutamine synthase gene glnA Heterogeneous introduction of wild-type Bacillus subtilis B. subtilis 168 orotate nucleoside monophosphate decarboxylase gene pyrF and orotic acid ribosyltransferase gene pyrE To achieve safe, efficient, and low-cost production of uracil.

Disclosed is compositions including L-carnitine and orotic acid and glyceryl phosphoryl ethanolamine for use in prevention of oxidative stress of cells. The compositions are also suitable for use in preventing and / or correcting neurodegenerative damages in a subject suffering from one Parkinson disease, Huntington disease and Alzheimer disease. Also disclosed is a colostrum-based dietary supplement enriched with L-carnitine and orotic acid and glyceryl phosphoryl ethanolamine.

Described herein are orotic acid esters and amides as nucleators for crystallizing molten poly(hydroxyalkanoates). The orotic acid esters and amides are soluble in the molten poly(hydroxyalkanoates) and have high nucleating efficiencies. The use of the orotic acid esters and amides described herein provide several advantages with respect to producing articles composed of thepoly(hydroxyalkanoates).

An object of the present invention is to provide a compound useful as an anti-tumor agent or the like; an intermediate thereof; and a pharmaceutical composition, an anti-tumor agent, and a dihydroorotate dehydrogenase inhibitor, each of which contains the compound. According to the present invention, there is provided a compound represented by General Formula (1) or a salt thereof:in the formula, Z1, Z2, and Z3 are the same as or different from each other and represent a nitrogen atom or CH; Z4 represents a nitrogen atom or a general formula of CR6; Z5 represents a nitrogen atom or a general formula of CR7 provided that at least one of Z1, Z2, Z3, Z4, or Z5 represents a nitrogen atom; R1 represents a general formula of CONHR8 or the like; R2 represents a C3-8 cycloalkyl group which may be substituted or the like; R3, R5, R6, and R7 are the same as or different from each other and represent a hydrogen atom, a halogen atom, or the like; R4 represents an aryl group which may be substituted or a heterocyclic group which may be substituted; R8 represents a general formula of SO2R9 or the like; and R9 represents an amino group which may be protected or the like.

The application discloses a genetically engineered bacterium for improving the yield of mevalonic acid as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. In order to solve the technical problems of low carbon atom economy and limited theoretical yield of MVA biosynthesis technology, the application takes Escherichia coli as a starting strain, overexpresses a bifunctional acetaldehyde-ethanol dehydrogenase mutant AdhE A267T / E568K gene adhE mut , an acetyl-CoA acyltransferase / HMG-CoA reductase gene mvaE , an HMG-CoA synthetase gene mvaS , and introduces a tetracycline-induced CRISPRi system to inhibit the expression of an orotate-5'-phosphate decarboxylase gene pyrF , so that the carbon flux is led from the growth of the strain to the synthesis of mevalonic acid. The genetically engineered bacterium provided by the application can produce mevalonic acid by fermentation with ethanol as a carbon source, and the yield reaches 0.89 g / g. The application provides a new idea for improving the carbon atom economy of mevalonic acid biological manufacturing.

The present invention relates to the use of nucleotide synthesis pathway inhibitors and macropinocytosis inhibitors for the treatment of tumors. The present disclosure provides the use of nucleotide synthetic pathway inhibitors and macropinocytosis inhibitors in the preparation of medicaments or kits for the treatment of tumors, where the nucleotide synthetic pathway inhibitors may include pyrimidine and / or purine synthetic pathway inhibitors such as orotic dehydrogenase (DHODH) inhibitors and phosphoribose pyrophosphate synthetase 1 (PRPS) inhibitors, the macropinocytosis inhibitor can comprise a macropinocytosis substrate uptake inhibitor, a PAK1 inhibitor, an EGFR signal pathway inhibitor, an ErbB signal pathway inhibitor, an NF-KB signal pathway inhibitor, an EREG inhibitor, a p65 inhibitor and an AREG inhibitor. The invention discloses a new way for activating macropinocytosis by using intracellular signals, provides a new insight for a regulation mechanism in tumor cells, and provides a new method for tumor treatment.

The invention discloses a preparation method of magnesium orotate, which comprises the following steps: S1, fully mixing orotic acid and orotic acid hydrolase in water to obtain an orotic acid suspension; the dosage of the orotic acid hydrolase is 5%-10% of the mass of the orotic acid; s2, adding magnesium oxide, and reacting at 50-70 DEG C until the solution is clear; the molar ratio of the amount of the orotic acid to the amount of the magnesium oxide is 2: (1.3-1.5); s3, concentrating, crystallizing and drying to obtain the magnesium orotate. According to the method, a certain amount of orotate hydrolase is added in the reaction, so that the hydrolysis ring opening of the orotate can be promoted, the reaction degree is increased, and the magnesium orotate product with relatively high yield and purity is obtained.

The present invention relates to 2-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I) and to a novel dosage regimen, as well as to their uses in the treatment of chronic inflammatory and / or autoimmune diseases. The compound of formula (I) mentioned inhibits dihydroorotate dehydrogenase (DHODH) and is known for the treatment and prevention of diseases, in particular its use in diseases in which there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

The application belongs to the technical field of screening of diagnostic markers for gestational diabetes, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application thereof. The application discloses a biomarker for predicting or diagnosing gestational diabetes, wherein the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrostercorol and cycloleucine, and more preferably comprises hypoxanthine, cortisol, dihydrostercorol, (3R, 4R)-D-erythrulose, creatine, cycloleucine and L-hydroxyproline. The seven biomarkers disclosed in the application can be used alone or in combination to predict or diagnose gestational diabetes in the early stage of pregnancy through plasma detection, effectively improve the early diagnosis rate of gestational diabetes, improve the prognosis of the disease, and have clinical use and promotion value.

The invention relates to the technical field of synthesis of drug intermediates, and particularly discloses a synthesis method of an inovirin key intermediate. Orotic acid and N, O-dimethyl hydroxylamine hydrochloride are used as starting raw materials, an intermediate 1 is prepared through amidation reaction, N, N '-carbonyldiimidazole is selected as a condensing agent to activate the reaction raw material orotic acid, and the conversion rate and the yield of the reaction are remarkably improved. According to the preparation method, the intermediate 1 and halogenated silane are subjected to a silanization reaction to prepare a silanide, and by introducing a silyl ether group, the solubility of the intermediate 1 is remarkably improved, and the reaction selectivity of a subsequent Grignard reaction and an addition reaction is improved, so that the feeding amount of halogenated benzonitrile compounds with relatively high cost is reduced. And finally, preparing the key intermediate of the inovirin through a Minisci reaction which is mild in condition and high in atom economic benefit. The route not only effectively reduces the production cost, but also ensures the purity and yield of the inovirin key intermediate.

The invention relates to the technical field of medicinal chemistry, in particular to salt of a dihydroorotate dehydrogenase inhibitor as well as a preparation method and application of the salt. The salt of the dihydroorotate dehydrogenase inhibitor is a salt of a compound as shown in a formula (I), the salt is hydrochloride, sulfate, hydrobromide or p-toluenesulfonate. Compared with the compound shown in the formula (I), the salt of the compound shown in the formula (I) has better solubility and bioavailability, and has excellent stability.